Clinical Trial Update: Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea [Phase 3]

View source ↗

Summary

Phase 3 clinical trial in Korea evaluating the immunogenicity and safety of the Vero cell-derived Japanese encephalitis vaccine has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Japanese Encephalitis

Drugs mentioned

• Vero Cell-derived Japanese Encephalitis Vaccine (Japanese encephalitis vaccine (Vero cell-derived))

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Japanese Encephalitis | Phase 3 | Status: COMPLETED